Open Access

Histopathological evaluation of cutaneous malignant melanoma: A retrospective study

  • Authors:
    • Daniela-Elena Gheoca Mutu
    • Adelaida Avino
    • Andra-Elena Balcangiu‑Stroescu
    • Mihai Mehedințu
    • Daniela Gabriela Bălan
    • Lăcrămioara Aurelia Brîndușe
    • Ana-Maria Popescu
    • Dorin Ionescu
    • Bogdan-Mihai Cristea
    • Luminiţa Florentina Tomescu
    • Cristian-Radu Jecan
    • Laura Răducu
  • View Affiliations

  • Published online on: April 20, 2022     https://doi.org/10.3892/etm.2022.11329
  • Article Number: 402
  • Copyright: © Gheoca Mutu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Malignant melanoma is a melanocytic neoplasm with a steadily increasing incidence worldwide. In order to define a proper diagnostic protocol and to establish an accurate prognostic method for the disease, specific biomarkers are of notable importance. Their contribution is also significant in the treatment of melanoma for the improvement of newer and more targeted therapeutic approaches. To emphasize the importance of specific immune markers in the diagnosis of melanoma, immunohistochemical analysis was performed on 56 formalin‑fixed paraffin‑embedded cutaneous melanomas. Besides the traditional prognostic factors, depth of invasion and mitotic rate, the markers tested in the present study were S100 protein family, Melan A, Ki67 and HMB‑45. The present results indicated that immunocytochemistry represents a valuable test in the diagnosis and treatment of malignant melanoma and each biomarker had different associations with the progression and prognosis of the disease. Patients with S100 expression were 4.83 times (95% CI=1.2‑20.8) more likely to suffer a relapse, whereas patients with a Ki67 expression of >30% had a 5.41‑fold higher risk (95% CI=1.3‑22.0). The correlation between S100 and the Breslow depth was statistically significant (r‑value: 0.43; P=0.027). In addition, the importance of a multidisciplinary team including a plastic surgeon, anatomopathologist and oncologist was highlighted.

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gheoca Mutu D, Avino A, Balcangiu‑Stroescu A, Mehedințu M, Bălan DG, Brîndușe LA, Popescu A, Ionescu D, Cristea B, Tomescu LF, Tomescu LF, et al: Histopathological evaluation of cutaneous malignant melanoma: A retrospective study. Exp Ther Med 23: 402, 2022
APA
Gheoca Mutu, D., Avino, A., Balcangiu‑Stroescu, A., Mehedințu, M., Bălan, D.G., Brîndușe, L.A. ... Răducu, L. (2022). Histopathological evaluation of cutaneous malignant melanoma: A retrospective study. Experimental and Therapeutic Medicine, 23, 402. https://doi.org/10.3892/etm.2022.11329
MLA
Gheoca Mutu, D., Avino, A., Balcangiu‑Stroescu, A., Mehedințu, M., Bălan, D. G., Brîndușe, L. A., Popescu, A., Ionescu, D., Cristea, B., Tomescu, L. F., Jecan, C., Răducu, L."Histopathological evaluation of cutaneous malignant melanoma: A retrospective study". Experimental and Therapeutic Medicine 23.6 (2022): 402.
Chicago
Gheoca Mutu, D., Avino, A., Balcangiu‑Stroescu, A., Mehedințu, M., Bălan, D. G., Brîndușe, L. A., Popescu, A., Ionescu, D., Cristea, B., Tomescu, L. F., Jecan, C., Răducu, L."Histopathological evaluation of cutaneous malignant melanoma: A retrospective study". Experimental and Therapeutic Medicine 23, no. 6 (2022): 402. https://doi.org/10.3892/etm.2022.11329